|1||NCT01752933||Completed||SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)||
||51||All||18 Years and older (Adult, Senior)||NCT01752933||SGI-110-03||December 2012||September 2015||September 2015||December 19, 2012||January 26, 2017||
|2||NCT03257761||Not yet recruiting||Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer||
||Other / NIH||
||90||All||18 Years and older (Adult, Senior)||NCT03257761||0S-16-18
|December 18, 2017||December 18, 2019||December 18, 2020||August 22, 2017||November 17, 2017||
† Study has passed its completion date and status has not been verified in more than two years.